Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 25/2/2021
SIETES contiene 93212 citas

 1 a 20 de 45 siguiente >>
Presentar resultados
Seleccionar todas
1.Tiene citas relacionadas Cita con resumen
Timsit J-F, Azoulay E, Schwebel C, Charles P-E, Cornet M, Souweine B, Klouche K, Jaber S, Trouillet J-L, Bruneel F, Argaud L, Cousson J, Meziani F, Gruson D, Paris A, Darmon M, Garrouste-Orgeas M, Navellou J-C, Foucrier A, Allaouchiche B, Das V, Gangneux J-P, Ruckly S, Maubon D, Jullien V, Wolff M, for the EMPIRICUS Trial Group. Empirical micafungin treatment and survival whithout invasive fungal infection in adults with ICU-acquired sepsis, Candida colonization, and multiple organ failure. The EMPIRICUS randomized clinical trial. JAMA 2016;316:1555-64. [Ref.ID 100904]
2.Tiene citas relacionadas
Siddharthan T, Karakousis PC, Checkley W. Empiral antifungal therapy in critically ill patients with sepsis. Another case of less is more in the ICU. JAMA 2016;316:1549-50. [Ref.ID 100903]
3. Cita con resumen
Dyer O. Experimental drug that injured UK volunteers resumes in human trials. BMJ 2015;350:h1831. [Ref.ID 98941]
4. Cita con resumen
Anónimo. Régorafénib: hypersensibilités multiorganiques. Prescrire 2014;34:749. [Ref.ID 98265]
5. Cita con resumen
Aubin F, Carbonnel F, Wendling D. The complexity of adverse side-effects to biological agents. Journal of Crohn's and Colitis 2013;7:257-62. [Ref.ID 96072]
6. Cita con resumen
Anónimo. Tétrazépam: syndromes de Lyell et autres troubles graves. Prescrire 2013;33:268. [Ref.ID 95338]
7.Tiene citas relacionadas
8.Tiene citas relacionadas Cita con resumen
Fowler VG, Allen KB, Moreira ED, Moustafa M, Isgro F, Boucher HW, Corey GR, Cameli Y, Betts R, Hartzel JS, Chan ISF, McNeely TB, Kartsonis NA, Guris D, Onorato MT, Smugar SS, DiNubile MJ, Sobanjo-ter Meulen A. Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. JAMA 2013;309:1368-78. [Ref.ID 95236]
9. Cita con resumen
Anónimo. Syndrome d'hypersensibilité multiorganique d'origine médicamenteuse. Prescrire 2012;32:832. [Ref.ID 93980]
10. Cita con resumen
Brunkhorst FM, Oppert M, Marx G, Bloos F, Ludewig K, Putensen C, Nierhaus A, Jaschinski U, Meier-Hellmann A, Weyland A, Gründing M, Moerer O, Riessen R, Seibel A, Ragaller M, Büchler MW, John S, Bach F, Spies C, Reill L, Fritz H, Kiehntopf M, Kuhnt E, Bogatsch H, Engel C, Loeffler M, Kollef MH, Reinhart K, Welte T, for the German Study Group Competence Network Sepsis (SepNet). Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial. JAMA 2012;307:2390-9. [Ref.ID 93235]
Hemelaar J. Minimising risk in first-in-man trials. Lancet 2007;369:1496-7. [Ref.ID 79994]
14. Cita con resumen
Stobbart L, Murtagh MJ, Rapley T, Ford GA, Louw SJ, Rodgers H. "We saw human guinea pigs explode". BMJ 2007;334:566-7. [Ref.ID 79557]
Mayor S. UK report recommends better planning for phase I drug trials. BMJ 2007;334:551. [Ref.ID 79550]
16.Tiene citas relacionadas Cita con resumen
Focosi D. Risk in drug trials. Lancet 2007;368:2206. [Ref.ID 78718]
17.Tiene citas relacionadas Cita con resumen
Ohresser M, Olive D, Vanhove B, Watier H. Risk in drug trials. Lancet 2007;368:2205-006. [Ref.ID 78717]
18.Tiene citas relacionadas Cita con resumen
Barnes MR, Holbrook J, Feild JA, Searls DB, Sanseau P. Risk in drug trials. Lancet 2007;368:2205. [Ref.ID 78716]
19.Tiene citas relacionadas Cita con resumen
Sugarman J, Levine C. Risk in drug trials. Lancet 2007;368:2205. [Ref.ID 78715]
20. Cita con resumen
Anónimo. Experts' final report sheds little new light on TGN1412 disaster. Scrip 2006;3217:3. [Ref.ID 78665]
Seleccionar todas
 1 a 20 de 45 siguiente >>